BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
- 15 January 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (2) , 843-844
- https://doi.org/10.1182/blood-2006-07-038000
Abstract
Our interpretation of these results differs from the accompanying Inside Blood commentary that concludes that the benefit of rituximab in BCL-6− cases was based on “only” 8 patients and that the 82% FFS of R-CHOP at 2 years in BCL-6+ DLBCL will be difficult to improve upon. These conclusions are based only on responding patients. When one considers all patients and excludes the effect of maintenance, which confounds FFS, the effect of rituximab in BCL-6− cases is based on 21 patients. Furthermore, the FFS of R-CHOP in BCL-6+ cases is approximately 40% at 3 years, a more mature time point given the 3.4-year median follow-up.Keywords
This publication has 12 references indexed in Scilit:
- Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyBlood, 2006
- CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2006
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin LymphomaThe Journal of Experimental Medicine, 2003
- Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biologyBlood, 2003
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacyBlood, 2002
- Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma CellsThe Journal of Experimental Medicine, 2001
- Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cellsBlood, 2001